— Fundamental Stock Analysis and Report Card
Located in Maplewood, MN, US. Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
Revenue, earnings and profitability.
Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.
Revenue History
Earnings History
Margins
Income & Cash Flow analysis.
An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.
Q1 2026 Total ($) | Q1 2026 Margin (%) | |
|---|---|---|
| Revenue | 2.0b -63.0m -3.0% | |
| Gross Income | 1.1b -17.0m -1.5% | 55% +0.8pp +1.6% |
| EBITDA | 213.0m -58.0m -21.4% | 11% -2.5pp -18.9% |
| Operating Income | 81.0m -71.0m -46.7% | 4% -3.3pp -45.0% |
| Net Income | 13.0m -124.0m -90.5% | 1% -6.0pp -90.2% |
| Earnings Per Share | 0.07 -0.7 -91.1% | |
| Operating Cash Flow | -189.0m -218.0m -751.7% | -9% -10.8pp -772.2% |
| Free Cash Flow | -273.0m -193.0m -241.2% | -14% -9.7pp -252.0% |
| Research & Development | 189.0m -4.0m -2.1% | 9% +0.1pp +1.0% |